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Background
This case highlights a rare but devastating neurologic condition, 
Stiff Person Syndrome (SPS). While symptoms of muscular 
rigidity and spasms are associated with numerous neuromuscular 
conditions, the association between SPS, autoimmune diabetes, 
and other autoimmune disorders such as thyroiditis, pernicious 
anemia, and vitiligo, could aid in the early diagnosis of this 
debilitating condition. 
Case Presentation
A 47-year-old African American female presented with six 
months of progressively worsening rigidity and spasticity of her 
axial muscles and extremities. The patient was in good health 
until one and a half years prior to admission when she lost 
consciousness while driving and was subsequently diagnosed 
with epilepsy. Her daughter was a passenger in the car and 
suffered a brief coma. Over the next year, the patient started 
having anxiety with increasingly more frequent and severe 
panic attacks. Six months prior to admission, she developed 
muscle stiffness and painful spasms that were so severe, she 
had difficulty ambulating and eventually became bed-bound. 
Magnetic Resonance Imaging (MRI) of the brain and spine did 
not reveal any pathology. Additionally, during the past year she 
was diagnosed with diabetes, which was unusual given her thin 
body habitus (Body-Mass Index of 20.9).
Investigations
The patient was admitted to the hospital for further work-up of 
her neuromuscular symptoms. On physical exam, her abdomen 
was tightly flexed and rigid, almost “board-like.” Musculoskeletal 
exam revealed significant spinal lordosis with tight contraction 
of the abdominal and paraspinal muscles. She also had several 
muscle contractures including bilateral externally rotated and 
adducted shoulders, bilateral elbow flexion, left wrist flexion, 
bilateral knee extension, bilateral ankle plantar flexion, and 
flexion of the left fingers (Figure 1a-b). There was no joint 
effusion or erythema. Neurologic exam revealed cranial nerves 
II-XII to be grossly intact. She had hypertonicity of the upper 
and lower extremities, abdominal, and paraspinal muscles, 
as well as intermittent myoclonic jerks of the limbs and neck 
that could be elicited by auditory or tactile stimuli. She had 
normal reflexes and no motor, sensory or cognitive deficits. 
In addition, telemetry monitoring revealed wide fluctuations 
in blood pressure (109/63 - 181/109 mmHg) and heart rate 
(104-140 beats per minute). Admission labs were significant for 
an elevated erythrocyte sedimentation rate, C-reactive protein 
and thyroid stimulating hormone (Table 1). 
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Figure 1A, B. Representative X-rays showing upper extremity contractures
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Differential Diagnosis
Neurology was consulted to evaluate the patient’s undiagnosed 
neuromuscular disorder. The differential diagnosis included Stiff 
Person Syndrome (SPS), neuromyotonia (Isaac’s syndrome), and 
chronic inflammatory demyelinating polyneuropathy (CIDP). 
However, there was also a suspicion of a psychological etiology 
to her symptoms. She had blood tests sent for anti- glutamic 
acid decarboxylase (GAD) 65, anti-voltage gated potassium 
channel, and anti-GM1 ganglioside antibodies to evaluate for 
SPS, neuromyotonia, and CIDP, respectively. Her anti-GAD65 
antibody level was above the upper limit of detection. She was also 
found to have markedly elevated anti-islet cell and anti-thyroid 
peroxidase antibodies. Her elevated anti-GAD65 antibody level, 
clinical presentation, and concurrent autoimmune diabetes and 
thyroiditis led to the diagnosis of SPS. She was evaluated for the 
paraneoplastic variant of SPS with anti-amphiphysin antibody, 
a paraneoplastic antibody panel, and Computed Tomography 
(CT) of the abdomen and pelvis, which were all negative. 
Treatment
She was started on a regimen of GABA-ergic and anti-spasticity 
medications including high-dose diazepam, tizanidine, 
baclofen, and dantrolene. She was then initiated on a five-day 
course of intravenous immunoglobulin (IVIG) with no relief 
in her symptoms. Joint manipulation under anesthesia was 
unsuccessful. Botulinum toxin injections mildly improved her 
range of motion. 
Outcome & Follow-up
Her hospital course was complicated by esophageal dysmotility 
causing aspiration pneumonia, Pseudomonas bacteremia, and 
ventilator-dependent respiratory failure. She was weaned from 
the ventilator and discharged to rehabilitation with plans of 
implanting a baclofen pump.
Discussion
Stiff person syndrome is a rare central nervous system (CNS) 
disorder characterized by progressive rigidity of the axial 
and proximal musculature with intermittent superimposed 
spasms. The age of onset of SPS is typically the fifth decade, 
and the disorder affects twice as many females as males.1 Two 
symptoms are key to the characterization of SPS: (1) stiffness of 
axial and proximal limb muscles due to continuous contraction 
and co-contraction of agonist and antagonist muscles and (2) 
superimposed intermittent painful spasms.2 In the classic form 
of this disorder, patients will experience aching and tightness in 
the neck and axial musculature and will develop hyperlordosis 
due to simultaneous contraction of abdominal and paraspinal 
muscles. The rigidity will spread to involve the proximal muscles 
of the lower extremities and is often asymmetric at onset.3 
Along with progressive stiffening of the musculature, patients 
also experience intermittent, sudden painful spasms which 
can be triggered by visual, auditory, or tactile stimuli, as well 
as emotional stress.4 In some cases, individuals can identify 
Table 1. Pertinent lab values
Lab Patient’s Lab Value Reference Range
CRP 4.20 0.0-0.8 mg/dL
ESR 56 0-20 mm/hr
Hemoglobin A1C 6.3 <5.7%
TSH 7.06 0.3-5.0 mIU/mL
Free T4 1.0 0.7-1.7 ng/dL
Free T43 1.5 2.0-4.4 pg/mL
Vitamin B12 729 210-950 pg/mL
Anti-Amphiphysin Ab Negative Negative
Anti-GAD65 Ab >30.0 <1.0 units
Anti-Islet Cell Ab 1:64 <1:4
Anti-Thyroglobulin Ab 0.1 <0.6 units
Anti-Thyroid Peroxidase (TPO) Ab >1000 0.0-100.0 units
TSH Receptor Ab <0.90 <1.75 units
Paraneoplastic Ab Panel (anti-Hu, anti-Ri, anti-Yo, cancer-associated 
retinopathy (CAR) Ab, Lambert-Eaton myasthenic syndrome (LEMS) Ab)
Negative Negative
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a major stressful life event that preceded the onset of their 
psychological and neuromuscular symptoms.5 The association 
between the exacerbation of the patient’s symptoms and 
emotional stress often leads to psychiatric evaluation. Early in 
the course of the disease, a patient’s neuromuscular symptoms 
may be non-specific, and the psychological features of anxiety 
and depression may dominate the clinical picture. This often 
leads to a diagnosis of a psychogenic movement disorder as 
their neuromuscular symptoms progress.5 Frequently, the 
misdiagnosis of a psychogenic movement disorder can be 
reinforced by the exacerbation of the patient’s symptoms by 
emotional stress and the improvement of symptoms with 
benzodiazepines. Finally, patients may suffer paroxysmal 
autonomic dysfunction, dysphagia from esophageal dysmotility, 
and seizures.6, 7 
Case reports have demonstrated an association between SPS 
and diabetes, but a major breakthrough in understanding the 
pathophysiology of SPS came in 1988 when Solimena et al 
identified antibodies against glutamic acid decarboxylase (GAD) 
in the serum and cerebrospinal fluid (CSF) of a patient with SPS 
and diabetes.8 GAD is the rate-limiting enzyme involved in the 
synthesis of γ-aminobutyric acid (GABA), the major inhibitory 
neurotransmitter in the CNS (Figure 2). The hypothesis that 
the loss of GABA-signaling in the CNS is the cause of SPS 
was supported by magnetic resonance spectroscopy showing 
a selective reduction in GABA in the sensorimotor cortex of 
patients with SPS.9 
Beyond anti-GAD antibodies, other autoantibodies targeting 
GABA synthesis, transport, and signaling have been recognized 
in patients with SPS (Table 2). More recently, antibodies 
targeting GABAA receptor-associated protein (GABARAP), 
have been identified in up to 70% of patients with SPS.11 A variant 
of SPS that occurs as a paraneoplastic syndrome has also been 
identified. This syndrome is most commonly associated with 
breast cancer but also has been observed in colon, lung, thymus 
cancers, as well as Hodgkin’s lymphoma. Autoantibodies against 
amphiphysin and gephyrin have been identified in the serum of 
patients with paraneoplastic SPS.2, 9, 10 
Clinical criteria for diagnosing SPS were last revised in 20092 as 
new discoveries regarding the pathophysiology of the disorder 
were made (Table 3). Beyond these diagnostic criteria, clinical 
response to diazepam is often included in the clinical criteria for 
the diagnosis of SPS. 
Table 2. Autoantibodies associated with stiff person syndrome
Autoantibody Function of Target Protein
Anti-GAD65 Rate-limiting enzyme in the synthesis of GABA
Anti-Amphiphysin
Synaptic vesicle protein involved in the recruitment of dynamin to sites 
of clathrin-mediated endocytosis which is involved in retrieving vesicle 
membrane from axon terminals after exoctyosis of GABA
Anti-Gephyrin
Tubulin-binding protein involved in the clustering of GABAA and glycine 
receptors at the postsynaptic membranes of inhibitory synapses
Anti-GABAA Receptor-Associated Protein (GABARAP)
Linker protein between gephyrin and GABAA receptors which is 
involved in postsynaptic clustering and stability of GABAA receptors at 
the post-synaptic membrane
Table 3. Dalakas diagnostic criteria for stiff person syndrome
Muscular rigidity in the limbs and axial (trunk) muscles, prominent in the abdominal and thoracolumbar paraspinals leading to a fixed 
deformity (hyperlordosis)
Continuous co-contraction of agonist and antagonist muscles, confirmed clinically and electrophysiologically
Episodic spasms precipitated by unexpected noises, tactile stimuli, or emotional upset
Absence of any other neurologic disease that could explain the stiffness and rigidity
Positive anti–glutamic acid decarboxylase (or amphiphysin) antibodies assessed by immunocytochemistry, Western blot,  
or radioimmunoassay
Adapted from: Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009;11:102-10.
GABA 
GAD 
Glutamate 
Figure 2.
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SPS is strongly associated with a variety of other autoimmune 
disorders, and the presence of these co-morbidities can be helpful 
in correctly diagnosing SPS. Autoimmune diabetes occurs 
in up to 35% of patients with SPS.2 In addition to anti-GAD 
antibodies, islet-cell antibodies have also been detected in the 
serum of patients with SPS and diabetes.12 Other autoimmune 
disorders, including thyroiditis, pernicious anemia, and vitiligo, 
have also been observed in patients with SPS. Patients with SPS 
presenting with these co-morbid autoimmune conditions have 
elevated levels of their respective autoantibodies, including 
thyroglobulin antibodies, thyroid peroxidase antibodies, and 
gastric parietal-cell antibodies.12 
Historically, the mainstays of treatment for SPS were 
GABA-enhancing medications and anti-spasticity drugs. 
However, as the autoimmune pathogenesis of SPS was identified, 
the utility of immunotherapy for SPS was investigated and 
has been validated. Currently, treatment of SPS consists of a 
combination of GABA-ergic and anti-spasticity medication as 
well as immunotherapy (Table 4).2 
Key Points
This patient’s case displays many of the clinical features classically 
observed in SPS. There was a prodrome of severe anxiety and 
she was able to identify a significant psychological stressor that 
triggered her functional decline. She developed progressive 
stiffness of the axial muscles leading to hyperlordosis and then 
developed stiffness of the extremities with the lower extremities 
locked in extension and upper extremities locked in flexion. She 
also had painful spasms elicited by auditory or tactile stimuli 
and she displayed autonomic instability on telemetry. She had 
markedly elevated anti-GAD65 antibodies and had co-morbid 
autoimmune disorders (autoimmune thyroiditis, latent 
autoimmune diabetes of adults) with associated circulating 
autoantibodies. Finally, she showed clinical improvement after 
treatment with diazepam.
Unfortunately, our patient did not display any clinical 
improvement following treatment with IVIG. However, in 
the clinical trial that demonstrated benefit of IVIG therapy for 
patients with SPS, bedridden patients were excluded.13 Thus, 
Table 4. Treatment options for patients with stiff person syndrome
GABA-Enhancing Drugs
Benzodiazepines (e.g. diazepam, clonazepam, 
alprazolam, lorazepam)
diazepam: 5-100 mg; clonazepam: 
2.5-6 mg; alprazolam: 2-4 mg; 
lorazepam: 6 mg
Central GABAA agonist
Antiepileptic drugs (e.g. vigabatrin, valproate, gabapentin, 
levetiracetam, tigabine)
vigabatrin: 2-3 g; valproate: 0.6-2 g; 
gabapentin 3600 mg; levetiracetam: 
2000 mg; tigabine: 6 mg
Augmentation of GABA signaling
Antispasticity Agents
Baclofen 10-60 mg GABAB agonist
Tizanidine 6 mg
Central α2-adrenergic action; 
inhibits norepinephrine release
Dantrolene 200-400 mg
Dissociates excitation-contraction 
coupling and blocks release of Ca2+ 
from the sarcoplasmic reticulum
Botulinum toxin A –
Neuromuscular junction blocking; 
prevents acetylcholine exocytosis
Immunotherapies
IV immunoglobulin 2 g/kg Immunosuppression/modulation
Rituximab 2 g (in two divided doses) B-cell depletion
Plasmapheresis 5-6 passes Immunosuppression/modulation
Corticosteroids Up to 60 mg Immunosuppression/modulation
Immunosuppressive agents (e.g. azathioprine, 
methotrexate, mycophenylate mofetil)
azathioprine: 2.5-3 mg/
kg; methotrexate: 15-20 mg; 
mycophenylate mofetil: 2-3 g
Immunosuppression/modulation
Adapted from: Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009;11:102-10
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this case highlights the importance of early diagnosis of this 
severely debilitating neurologic condition, as the least disability 
is observed in patients treated early in the course of their disease. 
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